Atherogenic Lipoprotein Particle Size and Concentrations and the Effect of Pravastatin in Children with Familial Hypercholesterolemia

Journal of Pediatrics

Volumn 152, Issue 6, 2008, Pages 873-878

  van der Graaf, Anouk ^a   Rodenburg, Jessica ^a   Vissers, Maud N ^a   Hutten, Barbara A ^a   Wiegman, Albert ^a   Trip, Mieke D ^a   Stroes, Erik S G ^a   Wijburg, Frits A ^a   Otvos, James D ^b   Kastelein, John J P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LIPOSCIENCE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIBLING; TREATMENT OUTCOME;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; CHILD; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; PARTICLE SIZE; PRAVASTATIN;

EID: 43549125037     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2007.11.043     Document Type: Article

References (28)

1. Goldstein J.L., Hobbs H.H., and Brown H.S. Familial hypercholesterolemia. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic Basis of Inherited Disease. 8th edition (2001), McGraw-Hill, New York 2863-2913
2. Blake G.J., Otvos J.D., Rifai N., and Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106 (2002) 1930-1937
3. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., and Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. Jama 260 (1988) 1917-1921
4. Campos H., Arnold K.S., Balestra M.E., Innerarity T.L., and Krauss R.M. Differences in receptor binding of LDL subfractions. Arterioscler Thromb Vasc Biol 16 (1996) 794-801
5. Flood C., Gustafsson M., Pitas R.E., Arnaboldi L., Walzem R.L., and Boren J. Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100. Arterioscler Thromb Vasc Biol 24 (2004) 564-570
6. Tribble D.L., Holl L.G., Wood P.D., and Krauss R.M. Variations in oxidative susceptibility among six low-density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93 (1992) 189-199
7. de Graaf J., Hak-Lemmers H.L., Hectors M.P., Demacker P.N., Hendriks J.C., and Stalenhoef A.F. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11 (1991) 298-306
8. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. The West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
9. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
10. Lariviere M., Lamarche B., Pirro M., Hogue J.C., Bergeron J., Gagne C., et al. Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia. Atherosclerosis 167 (2003) 97-104
11. Hoogerbrugge N., and Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis 146 (1999) 167-174
12. Cheung M.C., Austin M.A., Moulin P., Wolf A.C., Cryer D., and Knopp R.H. Effects of pravastatin on apolipoprotein-specific high-density lipoprotein subpopulations and low-density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 102 (1993) 107-119
13. Superko H.R., Krauss R.M., and DiRicco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol 80 (1997) 78-81
14. Vega G.L., Krauss R.M., and Grundy S.M. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 227 (1990) 81-94
15. Otvos J.D., Shalaurova I., Freedman D.S., and Rosenson R.S. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 160 (2002) 41-48
16. Wiegman A., Hutten B.A., de Groot E., Rodenburg J., Bakker H.D., Buller H.R., et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. Jama 292 (2004) 331-337
17. Friedewald W.T., Levy R.I., and Frederickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
18. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48 (2002) 171-180
19. Freedman D.S., Otvos J.D., Jeyarajah E.J., Shalaurova I., Cupples L.A., Parise H., et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem 50 (2004) 1189-1200
20. Festa A., Williams K., Hanley A.J., Otvos J.D., Goff D.C., Wagenknecht L.E., et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation 111 (2005) 3465-3472
21. McCrindle B.W., Urbina E.M., Dennison B.A., Jacobson M.S., Steinberger J., Rocchini A.P., et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 115 (2007) 1948-1967
22. O'Keefe Jr. J.H., Captain B.K., Jones P.G., and Harris W.S. Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern. Prev Cardiol 7 (2004) 154-160
23. van Tits L.J., Smilde T.J., van Wissen S., de Graaf J., Kastelein J.J., and Stalenhoef A.F. Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia. J Investig Med 52 (2004) 177-184
24. Guerin M., Egger P., Soudant C., Le Goff W., van Tol A., Dupuis R., et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163 (2002) 287-296
25. Tornvall P., Bavenholm P., Landou C., de Faire U., and Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 88 (1993) 2180-2189
26. Guerin M., Dolphin P.J., Talussot C., Gardette J., Berthezene F., and Chapman M.J. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 15 (1995) 1359-1368
27. Guerin M., Lassel T.S., Le G.W., Farnier M., and Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
28. Luo Y., and Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J Clin Invest 105 (2000) 513-520